Key result
Elevated PASP linked to ~246% higher cardiovascular admission or death risk in severe CVD pregnancies.
Why the study?
To analyze maternal complications and pregnancy outcomes in pregnant women with severe CVD, and evaluate the predictive value of PASP and NT-proBNP.
Does the combination of PASP and NT-proBNP predict CVD-related readmission or death in pregnant women with severe cardiovascular disease?
Observational (n=158)
No
Does the combination of PASP and NT-proBNP predict CVD-related readmission or death in pregnant women with severe cardiovascular disease?
The combination of PASP and NT-proBNP provides useful prognostic information for predicting cardiovascular-related hospitalization or death in pregnant women with severe cardiovascular disease.
Answers are grounded in this paper and cite their sources.
May support PASP-based risk stratification in severe CVD pregnancies; leaves open prospective validation of combined biomarkers to guide care.
Objective To analyze maternal complications and pregnancy outcomes in pregnant women with severe cardiovascular disease (CVD), and explore the predictive value of pulmonary artery systolic pressure (PASP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for these outcomes. Method A retrospective observational study was conducted on pregnant women with severe CVD who were admitted to our hospital between December 2019 to August 2025. Demographic data, delivery mode, laboratory and imaging examination results, and post-partum follow-up data were collected. The primary outcome was CVD-related readmission or death during follow-up. Results A total of 158 patients (168 pregnancies) were included, with median follow-up of 1.8 (interquartile range 3.0) years. Among them, 86 cases achieved successful delivering, including 14 vaginal deliveries and 72 cesarean sections. Compared with the PASP < 50 mmHg group, the PASP ≥ 50 mmHg group had a significantly higher medical abortion rate (34.5% vs. 12.2%), and a notably lower average birth weight (2247.5 g vs. 3042.5 g, P = 0.007). ROC curve analysis revealed that the combined PASP + NT-proBNP index exhibited the highest predictive efficacy for the primary outcome (AUC = 0.748, P = 0.001), followed by NT-proBNP alone (AUC = 0.724, P = 0.003) and PASP alone (AUC = 0.664, P = 0.028). Kaplan-Meier survival analysis demonstrated that pregnant women with elevated PASP (≥ 44.5 mmHg; HR = 3.456, 95% CI: 1.367–8.734; P = 0.009) or NT-proBNP (≥ 241.25 pg/mL; HR = 6.863, 95% CI: 2.432–19.370; P < 0.001) had a significantly increased risk of cardiovascular-related hospitalization or death during follow-up. Conclusion PASP may serve as a reference indicator for guiding perinatal risk assessment in pregnant women with severe CVD, while NT-proBNP could help optimize the long-term prognostic prediction of this population. The combined application of these two parameters might provide a preliminary basis for risk stratification, which may assist in clinical decision-making regarding perinatal management and long-term prognosis monitoring.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) conducted an observational in Severe cardiovascular disease in pregnancy (n=158). Elevated pulmonary artery systolic pressure (PASP ≥ 44.5 mmHg) vs. PASP < 44.5 mmHg was evaluated on Cardiovascular-related hospitalization or death (HR 3.456, 95% CI 1.367-8.734, p=0.009). Elevated pulmonary artery systolic pressure (≥ 44.5 mmHg) significantly increased the risk of cardiovascular-related hospitalization or death in pregnant women with severe cardiovascular disease (HR 3.456).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: